<DOC>
	<DOCNO>NCT00289757</DOCNO>
	<brief_summary>The aim study evaluate long-term persistence hepatitis A antibodies 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 20 year subject receive first dose 2 dose vaccination schedule hepatitis A vaccine .</brief_summary>
	<brief_title>Long-Term Immune Persistence GlaxoSmithKline Biologicals ' Inactivated Hepatitis A Vaccine , Injected According 0 , 6-month Schedule</brief_title>
	<detailed_description>This long-term follow-up study Years 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 20 primary vaccination GSK Biologicals ' hepatitis A vaccine ( two-dose schedule ) . To evaluate long-term antibody persistence , volunteer donate blood sample Years 11 , 12 , 13 , 14,15 , 16 , 17 , 18 , 19 20 first vaccine dose primary vaccination course determine anti-hepatitis A ( anti-HAV ) antibody concentration If subject become seronegative anti-HAV antibody long-term blood sampling time point ( i.e . Years 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 20 year ) , he/ offer additional vaccine dose . A blood sample take day additional vaccination , 14 day one month additional vaccination evaluate immune response follow vaccination . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 include extend follow period Year 20 primary vaccination . The study 10 phase ( 100576 , 100577 , 100578 , 100579 , 100580 , 111028 , 111029 , 111030 , 111031 , 111032 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<criteria>Subjects receive least one dose study vaccine primary study Written inform consent obtain subject blood sample visit year .</criteria>
	<gender>All</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Havrixâ„¢</keyword>
	<keyword>Hepatitis A</keyword>
</DOC>